What does this research mean for the field?

GLP-1 receptor agonists (GLP-1RAs) are associated with a wide range of adverse events (AEs) across various indications. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to assess the real-world adverse events associated with GLP-1 receptor agonists (GLP-1RAs).

March 12, 2026Obesity3 citationsOpen Access

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )

View Full Paper

DSDavid Stone MPMary C. Playdon SHS. D. Hursting

Key Points

The research aims to assess the real-world adverse events associated with GLP-1 receptor agonists (GLP-1RAs).
Utilized the FDA Adverse Event Reporting System (FAERS) dataset
Analyzed various adverse events linked to GLP-1RAs across different conditions
Monitored long-term safety implications
Identified a broad range of adverse events corresponding to GLP-1RAs
Highlighted the necessity for careful clinical monitoring
Demonstrated the role of real-world evidence in enhancing safety communications

Abstract

GLP-1RAs are linked to a broad range of AEs across indications. These findings stress the need for careful clinical monitoring and long-term safety evaluation. This study also illustrates how real-world evidence can inform safety communications, as well as hypothesis generation for research on next-generation GLP-1RAs.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )

Key Points

Abstract

Cite This Study